KRAS,BRAF oncogene mutations and tissue specific promoter hypermethylation of tumor suppressor SFRP2,DAPK1,MGMT,HIC1 and p16 genes in colorectal cancer patients
Free accessResearch articleFirst published online May, 2016
KRAS,BRAF oncogene mutations and tissue specific promoter hypermethylation of tumor suppressor SFRP2,DAPK1,MGMT,HIC1 and p16 genes in colorectal cancer patients
Colorectal cancer is a serious disease that causes significant morbidity and mortality in developed countries. Genetic changes, such as mutations in proto-oncogenes and DNA repair genes, and loss of function in the tumor suppressor genes cause colorectal cancer development. Abnormal DNA methylation is also known to play a crucial role in colorectal carcinogenesis.
OBJECTIVE:
In this study, frequencies of KRAS and BRAF mutations, promoter hypermethylation profiles of SFRP2, DAPK1, MGMT, HIC1 and p16 genes, and possible associations between hypermethylation of these genes and KRAS and BRAF mutations were aimed to find out.
METHODS:
Ninety three colorectal cancer tissues and 14 normal colon mucosas were included in the study. Common twelve KRAS gene mutation were investigated with using reverse-hybridization strip assay method. BRAF V600E mutations were investigated with RFLP method. Hypermethylation status of five tumor suppressor genes were detected by using reverse-hybridization strip assay method after bisulfite modification of DNA.
RESULTS:
KRAS and BRAF mutation frequencies were determined as 54.84% and 12.9%, respectively. Promoter hypermethylation frequencies of tumor suppressor genes SFRP2, DAPK1, MGMT, HIC1 and p16 were determined as 66.7%, 45.2%, 40.9%, 40.9% and 15.1%, respectively. Statistically significant associations were found between BRAF mutation and SFRP2 and p16 tumor suppressor genes hypermethylation (SFRP2; p= 0.005, p16; p= 0.016). Compared to rectum, SFRP2 (p= 0.017) and MGMT (p= 0.013) genes have statistically significantly higher promoter hypermethylation in colon.
CONCLUSIONS:
Results of the current study have confirmed that KRAS mutations and SFRP2 hypermethylation can be used as genetic markers in colorectal cancer.
AdjeiAABlocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst2001; 93(14): 1062-1074.
2.
AhujaN, MohanAL, LiQ, et al. Association between CpG island methylation and microsatellite instability in colorectal cancer. Cancer Res1997; 57(16): 3370-3374.
3.
Al-MullaF, GoingJJ, SowdenET, WinterA, PickfordIR, BirnieGD. Heterogeneity of mutant versus wild-type Ki-ras in primary and metastatic colorectal carcinomas, and association of codon-12 valine with early mortality. J Pathol1998; 185(2): 130-138.
4.
AndreyevHJ, NormanAR, CunninghamD, et al. Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer2001; 85(5): 692-696.
5.
AnjumR, RouxPP, BallifBA, GygiSP, BlenisJ. The tumor suppressor DAP kinase is a target of RSK-mediated survival signaling. Curr Biol2005; 15(19): 1762-1767.
6.
ArringtonAK, HeinrichEL, LeeW, et al. Prognostic and predictive roles of KRAS mutation in colorectal cancer. Int J Mol Sci2012; 13(10): 12153-13168.
7.
ArslanS, AkkurtI, KoksalB, KaradayiS, OzdemirO. Predictive significance of KRAS point mutation in patients with non-small cell lung carcinoma relation to smoking and asbestos exposure in middle Anatolia population. Healthmed2010; 4: 715-719.
8.
ArslanS, DoganT, KoksalB, et al. Tumoral tissue specific promoter hypermethylation of distinct tumor suppressor genes in a case with nonsmall cell lung carcinoma: A case report. Lung India2008; 25(4): 148-151.
9.
BergM, DanielsenSA, AhlquistT, et al. DNA sequence profiles of the colorectal cancer critical gene set KRAS-BRAF-PIK3CA-PTEN-TP53 related to age at disease onset. PLoS ONE2010; 5(11): e13978.
10.
BrinkM, de GoeijAF, WeijenbergMP, et al. K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study. Carcinogenesis2003; 24(4): 703-710.
11.
ChangSC, LinJK, YangSH, WangHS, LiAF, ChiCW. Relationship between genetic alterations and prognosis in sporadic colorectal cancer. Int J Cancer2006; 118(7): 1721-1727.
12.
DahabrehIJ, TerasawaT, CastaldiPJ, TrikalinosTA. Systematic review: Anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer. Ann Intern Med2011; 154(1): 37-49.
13.
DengG, BellI, CrawleyS, et al. BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer. Clin Cancer Res2004; 10:191-195.
14.
de VogelS, WeijenbergMP, HermanJG, et al. MGMT and MLH1 promoter methylation versus APC, KRAS and BRAF gene mutations in colorectal cancer: Indications for distinct pathways and sequence of events. Ann Oncol2009; 20(7): 1216-1222.
15.
DiehlJA, ZindyF, SherrCJ. Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway. Genes Dev1997; 11(8): 957-972.
16.
Di NicolantonioF, MartiniM, MolinariF, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol2008; 26(35): 5705-5712.
17.
DongSM, LeeEJ, JeonES, ParkCK, KimKM. Progressive methylation during the serrated neoplasia pathway of the colorectum. Mod Pathol2004; 18(2): 170-178.
18.
EstellerM, ToyotaM, Sanchez-CespedesM, et al. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. Cancer Res2000; 60(9): 2368-2371.
19.
GuanRJ, FuY, HoltPR, PardeeAB. Association of K-ras mutations with p16 methylation in human colon cancer. Gastroenterology1999; 116(5): 1063-1071.
20.
HawkinsNJ, LeeJH, WongJJ, KwokCT, WardRL, HitchinsMP. MGMT methylation is associated primarily with the germline C>T SNP (rs16906252) in colorectal cancer and normal colonic mucosa. Mod Pathol2009; 22(12): 1588-1599.
21.
HeinemannV, StintzingS, KirchnerT, BoeckS, JungA. Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR. Cancer Treat Rev2009; 35(3): 62-267.
22.
HuangZ, LiL, WangJ. Hypermethylation of SFRP2 as a potential marker for stool-based detection of colorectal cancer and precancerous lesions. Dig Dis Sci2007; 52(9): 2287-2291.
23.
ImamuraY, MorikawaT, LiaoX, et al. Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers. Clin Cancer Res2012; 18(17): 4753-4763.
24.
IssaJP. Aging, DNA methylation and cancer. Crit Rev Oncol Hematol1999; 32(1): 31-43.
25.
KawakamiK, RuszkiewiczA, BennettG, et al. DNA hypermethylation in the normal colonic mucosa of patients with colorectal cancer. Br J Cancer2006; 94(4): 593-598.
26.
LeeM, HanWS, KimOK, et al. Prognostic value of p16INK4a and p14ARF gene hypermethylation in human colon cancer. Pathol Res Pract2006; 202(6): 415-424.
27.
LiHT, LuYY, AnYX, WangX, ZhaoQC. KRAS, BRAF and PIK3CA mutations in human colorectal cancer: Relationship with metastatic colorectal cancer. Oncol Rep2011; 25(6): 1691-1697.
28.
LiggettWH, SidranskyD. Role of the p16 tumor suppressor gene in cancer. J Clin Oncol1998; 16(3): 1197-1206.
29.
MinooP, BakerK, GoswamiR, et al. Extensive DNA methylation in normal colorectal mucosa in hyperplastic polyposis. Gut2006; 55(10): 1467-1474.
30.
MoerkerkP, ArendsJW, van DrielM, de BruïneA, de GoeijA, ten KateJ. Type and number of Ki-ras point mutations relate to stage of human colorectal cancer. Cancer Res1994; 54(13): 3376-3378.
31.
MortonRF, HammondEH. ASCO Provisional Clinical Opinion: KRAS, Cetuximab, and Panitumumab-Clinical Implications in Colorectal Cancer. J Oncol Pract2009; 5(2): 71-72.
32.
NambaH, NakashimaM, HayashiT, et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab2003; 88(9): 4393-4397.
33.
NashGM, GimbelM, ShiaJ, et al. KRAS mutation correlates with accelerated metastatic progression in patients with colorectal liver metastases. Ann Surg Oncol2010; 17(2): 572-578.
34.
NicollG, CrichtonDN, McDowellHE, KernohanN, HupTR, ThompsonAM. Expression of the Hypermethylated in Cancer gene (HIC-1) is associated with good outcome in human breast cancer. Br J Cancer2001; 85(12): 1878-1882.
35.
NoshoK, IraharaN, ShimaK, et al. Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. PLoS ONE2008; 3(11): e3698.
36.
OginoS, MeyerhardtJA, IraharaN, et al. KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. Clin Cancer Res2009; 15(23): 7322-7329.
RattnerA, HsiehJC, SmallwoodPM, et al. A family of secreted proteins contains homology to the cysteine-rich ligand-binding domain of frizzled receptors. PNAS1997; 94(7): 2859-2863.
39.
RichmanSD, SeymourMT, ChambersP, et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol2009; 27(35): 5931-5937.
40.
SamowitzWS, CurtinK, SchafferD, RobertsonM, LeppertM, SlatteryML. Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study. Cancer Epidemiol Biomarkers Pre2000; 9(11): 1193-1197.
41.
ShannonBA, IacopettaBJ. Methylation of the hMLH1, p16, and MDR1 genes in colorectal carcinoma: associations with clinicopathological features. Cancer Letters2001; 167(1): 91-97.
42.
ShenL, KondoY, RosnerGL, et al. MGMT promoter methylation and field defect in sporadic colorectal cancer. J Natl Cancer Inst2005; 97(18): 1330-1338.
43.
ShilohR, BialikS, KimchiA. The DAPK family: A structure-function analysis. Apoptosis2014; 19(2): 286-297.
44.
SiegelR, DeSantisC, JemalA. Colorectal cancer statistics, 2014. CA: A cancer journal for clinicians2014; 64(2): 104-117.
45.
SienaS, Sartore-BianchiA, Di NicolantonioF, BalfourJ, BardelliA. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst2009; 101(19): 1308-1324.
46.
SmithG, BoundsR, WolfH, SteeleRJC, CareyFA, WolfCR. Activating K-Ras mutations outwith `hotspot' codons in sporadic colorectal tumours-implications for personalised cancer medicine. Br J Cancer2010; 102(4): 693-703.
47.
SuiC, WangG, ChenQ, MaJ. Variation risks of SFRP2 hypermethylation between precancerous disease and colorectal cancer. Tumor Biology2014; 35(10): 10457-10465.
48.
SuzukiH, WatkinsDN, JairKW, et al. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet2004; 36(4): 417-422.
49.
SweeneyC, BoucherKM, SamowitzWS, et al. Oncogenetic tree model of somatic mutations and DNA methylation in colon tumors. Genes, Chromosomes and Cancer2009; 48(1): 1-9.
50.
TanakaN, HuttenhowerC, NoshoK, et al. Novel application of structural equation modeling to correlation structure analysis of CpG island methylation in colorectal cancer. Am J Pathol2010; 177(6): 2731-2740.
51.
TolJ, PuntCJ. Monoclonal antibodies in the treatment of metastatic colorectal cancer: A review. Clin Ther2010; 32(3): 437-453.
52.
Van CutsemE, KöhneCH, LángI, et al. Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status. J Clin Oncol2011; 29(15): 2011-2019.
53.
WangDR, TangD. Hypermethylated SFRP2 gene in fecal DNA is a high potential biomarker for colorectal cancer noninvasive screening. World J Gastroenterol2008; 14(4): 524-531.
54.
WuCM, TangR, WangJY, ChangchienCR, HsiehLL. Frequency and spectrum of K-RAS codons 12 and 13 mutations in colorectal adenocarcinomas from Taiwan. ancer Genet Cytogenet2005; 158(1): 55-60.
55.
YenLC, UenYH, WuDC, et al. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab. Ann Surg2010; 251(2): 254-260.
56.
YokotaT, UraT, ShibataN, et al. BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. Br J Cancer2011; 104(5): 856-862.
